Prospect Capital Corporation Closes $764 Million of New Investments in Fiscal Year June 2024
Prospect Capital (NASDAQ: PSEC) closed $764 million of new investments during its fiscal year ended June 30, 2024, investing in 38 new and existing portfolio companies. Notably, 91% of PSEC's originations were first lien, senior secured loans. Key investments included:
- $56 million in clinical trial services
- $60 million in business process outsourcing
- $26 million in healthcare services
- $30 million in direct-to-consumer marketing
- $37 million in logistics services
- $13 million in furniture provision
- $10 million in home-based infusion pharmacy services
- $20 million in branded jewelry design
As of October 14, 2024, Prospect is processing an investment pipeline of over $350 million, with transactions still under due diligence and analysis.
Prospect Capital (NASDAQ: PSEC) ha chiuso 764 milioni di dollari di nuovi investimenti durante l'anno fiscale terminato il 30 giugno 2024, investendo in 38 nuove ed esistenti aziende del portafoglio. In particolare, il 91% delle originazioni di PSEC erano prestiti senior garantiti di primo grado. Gli investimenti chiave includevano:
- 56 milioni di dollari in servizi per prove cliniche
- 60 milioni di dollari in outsourcing dei processi aziendali
- 26 milioni di dollari in servizi sanitari
- 30 milioni di dollari in marketing diretto al consumatore
- 37 milioni di dollari in servizi logistici
- 13 milioni di dollari per la fornitura di mobili
- 10 milioni di dollari per servizi farmaceutici di infusione a domicilio
- 20 milioni di dollari in design di gioielli di marca
Al 14 ottobre 2024, Prospect sta elaborando un pipeline di investimenti di oltre 350 milioni di dollari, con transazioni ancora in fase di due diligence e analisi.
Prospect Capital (NASDAQ: PSEC) cerró 764 millones de dólares en nuevas inversiones durante su año fiscal que terminó el 30 de junio de 2024, invirtiendo en 38 nuevas y existentes compañías de la cartera. Notablemente, el 91% de las originaciones de PSEC fueron préstamos garantizados senior de primer grado. Las inversiones clave incluyeron:
- 56 millones de dólares en servicios de ensayos clínicos
- 60 millones de dólares en externalización de procesos empresariales
- 26 millones de dólares en servicios de salud
- 30 millones de dólares en marketing directo al consumidor
- 37 millones de dólares en servicios logísticos
- 13 millones de dólares en provisión de mobiliario
- 10 millones de dólares en servicios de farmacia de infusión a domicilio
- 20 millones de dólares en diseño de joyas de marca
Al 14 de octubre de 2024, Prospect está procesando una cartera de inversiones de más de 350 millones de dólares, con transacciones aún en diligencia debida y análisis.
프로스펙트 캐피탈(NASDAQ: PSEC)은 2024년 6월 30일 종료된 회계연도 동안 7억 6천4백만 달러의 신규 투자를 마감하며, 38개의 신규 및 기존 포트폴리오 회사에 투자했습니다. 특히, 91%의 PSEC의 기원은 1차 담보 대출이었습니다. 주요 투자 항목은 다음과 같습니다:
- 5,600만 달러의 임상 시험 서비스
- 6,000만 달러의 비즈니스 프로세스 아웃소싱
- 2,600만 달러의 의료 서비스
- 3,000만 달러의 직접 소비자 마케팅
- 3,700만 달러의 물류 서비스
- 1,300만 달러의 가구 제공
- 1,000만 달러의 가정용 주입 약국 서비스
- 2,000만 달러의 브랜드 주얼리 디자인
2024년 10월 14일 현재, 프로스펙트는 3억 5천만 달러 이상의 투자 파이프라인을 처리하고 있으며, 거래는 여전히 실사 및 분석 중에 있습니다.
Prospect Capital (NASDAQ: PSEC) a clôturé 764 millions de dollars de nouveaux investissements au cours de son exercice fiscal se terminant le 30 juin 2024, en investissant dans 38 nouvelles et anciennes entreprises de portefeuille. Notamment, 91% des origines de PSEC étaient des prêts garantis senior de premier rang. Les investissements clés comprenaient :
- 56 millions de dollars en services d'essai clinique
- 60 millions de dollars en externalisation des processus métier
- 26 millions de dollars en services de santé
- 30 millions de dollars en marketing direct aux consommateurs
- 37 millions de dollars en services logistiques
- 13 millions de dollars en fourniture de mobilier
- 10 millions de dollars en services de pharmacie d'infusion à domicile
- 20 millions de dollars en conception de bijoux de marque
Au 14 octobre 2024, Prospect traite un pipeline d'investissement de plus de 350 millions de dollars, avec des transactions encore sous diligence raisonnable et analyse.
Prospect Capital (NASDAQ: PSEC) hat im Geschäftsjahr zum 30. Juni 2024 insgesamt 764 Millionen US-Dollar in neue Investitionen abgeschlossen und in 38 neue und bestehende Portfoliounternehmen investiert. Bemerkenswerterweise waren 91% der Originationen von PSEC besicherte Senior-Darlehen erster Rang. Zu den wichtigsten Investitionen gehörten:
- 56 Millionen US-Dollar in klinische Prüfdienste
- 60 Millionen US-Dollar in Geschäftsprozess-Outsourcing
- 26 Millionen US-Dollar in Gesundheitsdienste
- 30 Millionen US-Dollar im Direktvertrieb an Verbraucher
- 37 Millionen US-Dollar in Logistikdienstleistungen
- 13 Millionen US-Dollar für die Bereitstellung von Möbeln
- 10 Millionen US-Dollar für häusliche Infusionsapothekerdienste
- 20 Millionen US-Dollar für das Design von Marken-Schmuck
Stand 14. Oktober 2024 bearbeitet Prospect eine Investitionspipeline von über 350 Millionen US-Dollar, mit Transaktionen, die sich noch in der Due Diligence und Analyse befinden.
- Closed $764 million of new investments in fiscal year 2024
- 91% of originations were first lien, senior secured loans
- Diversified investments across multiple sectors
- Processing a pipeline of over $350 million in potential investments
- None.
Insights
Prospect Capital 's $764 million in new investments during fiscal year 2024 demonstrates strong deal flow and capital deployment. The
Key highlights include:
- Investments in high-growth sectors like healthcare, technology and business services
- Focus on add-on acquisitions and refinancing, suggesting support for portfolio company growth
- Potential for income generation through interest payments on loans
The
Prospect Capital's investment strategy aligns with current market trends, focusing on resilient sectors like healthcare and technology. The emphasis on first lien loans provides a degree of downside protection in an uncertain economic environment. The company's ability to close deals across various industries demonstrates adaptability and a broad network.
Key market implications:
- Increased competition for quality deals may pressure yields
- Rising interest rates could benefit PSEC's floating rate loans
- Economic uncertainties may increase default risks in certain sectors
Investors should monitor PSEC's ability to maintain deal flow and loan quality as market conditions evolve. The company's performance relative to peers in the BDC sector will be a important benchmark for assessing its competitive position and potential stock performance.
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”) closed
Selected investments in both new and existing portfolio companies during fiscal year 2024 include:
$56 million of first lien loans to refinance the debt of a provider of clinical trial services. The company is a clinical development services provider that operates and conducts clinical trials for pharmaceutical and biotechnology customers.$60 million of primarily first lien loans to finance an acquisition of a provider of business process outsourcing solutions. The company provides customer experience services and business process outsourcing services, which includes customer call centers, online chat, text message, and general ‘contact center as a service’.$26 million of primarily first lien loans to finance an acquisition of a healthcare services provider. The company is a detox and rehabilitation provider that offers residential inpatient treatment, partial hospital programs, and intensive outpatient care in multiple restore facilities.$30 million of a first lien loan to finance a shareholder distribution for a direct-to-consumer marketing company. The company is a direct marketer and distributor of modern-era government-issued gold and silver coins.$37 million of primarily first lien loans to finance an add-on acquisition and shareholder distribution for a logistics service provider. The company provides turnkey inventory management and transportation services.$13 million of a first lien loan to finance an add-on acquisition by a furniture provider. The company provides furniture and furnishings to residential and commercial end markets, including churches, hospitality, offices, restaurants, and schools.$10 million of first lien loans for a healthcare services provider in a secondary transaction. The company is a home-based infusion pharmacy services provider serving patients with chronic conditions.$20 million of first lien loans to finance a shareholder distribution of a branded jeweler designer. The company is a designer and retailer of distinctive handcrafted gold-plated women’s jewelry decorated with semi-precious stones, including necklaces, bracelets, rings, and earrings.
In addition, as of October 14, 2024, Prospect is processing an investment pipeline of more than
The investment pipeline includes transactions for which a formal mandate, letter of intent, or signed commitment may or may not have been issued. The consummation of any of the investments in this pipeline depends upon, among other things, one or more of the following: satisfactory completion of Prospect’s due diligence investigation of the prospective portfolio company, Prospect’s acceptance of the terms and structure of such investment, and the execution and delivery of transaction documentation satisfactory to Prospect. In addition, Prospect may sell all or a portion of these investments and certain of these investments may result in the repayment of existing investments. Prospect cannot assure you that it will make any of these investments or that Prospect will sell all or any portion of these investments.
About Prospect Capital Corporation
Prospect is a business development company that focuses on lending to and investing in private businesses. Prospect’s investment objective is to generate both current income and long-term capital appreciation through debt and equity investments.
Prospect has elected to be treated as a business development company under the Investment Company Act of 1940 (“1940 Act”). Prospect is required to comply with a series of regulatory requirements under the 1940 Act as well as applicable NASDAQ, federal and state rules and regulations. We have elected to be treated as a regulated investment company under the Internal Revenue Code of 1986.
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, whose safe harbor for forward-looking statements does not apply to business development companies. Any such statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that we may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements. Such statements speak only as of the time when made, and we undertake no obligation to update any such statement now or in the future.
For further information, contact:
Grier Eliasek, President and Chief Operating Officer
Telephone (212) 448-0702
FAQ
What was the total value of new investments closed by PSEC in fiscal year 2024?
How many new and existing portfolio companies did PSEC invest in during fiscal year 2024?
What percentage of PSEC's originations in fiscal year 2024 were first lien, senior secured loans?